Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 January 2020 | Story Eugene Seegers | Photo Kaleidoscope Studios | Sonia Small
Kaleidoscope - Dr Maria Madiope - New South Campus Principal
Dr Maria Madiope took over the reins of the UFS South Campus at the beginning of January 2020.

The Council of the University of the Free State (UFS) approved the appointment of Dr Maria ‘Marinkie’ Madiope as Principal of the South Campus for Open Distance Learning (ODL) during a meeting held on 20 September 2019. Dr Madiope took over the reins of the UFS South Campus at the beginning of January 2020.

Educator at heart

Educating and empowering others are key aspects of Dr Madiope's life. She has served as the Director for University Teaching and Learning at Unisa since 2015 and takes her role incredibly seriously, achieving a transformative curriculum at the colleges under her care since her appointment.

Dr Madiope holds a PhD in Education from Unisa, with a specialisation in Didactics; her next two degrees where completed at the then RAU, which is today known as the University of Johannesburg: a BEd in 1999, followed by an MEd in 2001, both specialising in Computer-based Instruction. She previously obtained her BA Ed in 1985 and a BEd in 1988 from the University of the North. Her initial training as a teacher was from the Hebron College of Education from 1980-81.

Dr Madiope is also the editor of the only journal in ODL, Progressio, since 2016. Her expertise in E-learning is another of her strong points. Together with her team, Dr Madiope designed and developed the first online course in Curriculum Transformation, which is being piloted at Unisa. Her work has been rewarded with awards such as the Unisa Gender Activism: Advocacy and Promotion of Women’s Rights 2013, Unisa Woman of the Year 2013, and Unisa Best Performer 2013.

Dr Madiope brings with her a wealth of experience to UFS and her vision is to increase access to a wider base of learners with potentially having more African learners enrolled. The first point of call would be to have more learners coming from Lesotho and then the rest of the SADEC region, having the UFS become a leading distance-learning university. One of the key projects that Dr Madiope wishes to tackle is early childhood development. “I believe in educating educators to ensure that they are best equipped to provide the latest and relevant Early childhood and development practices that are on par with the rest of the world,” she says.

Community leader

In addition to being an experienced educator and administrator, Dr Madiope is instrumental in community projects that lie close to her heart. Whether it is large-scale advocacy for women’s rights or her personal involvement in the supply of sanitary towels for schoolgirls as part of a programme to empower the girl child through exposing them to options, it is humbling to watch her compassion in action.

She further intends to strengthen the relationship of the university with TVET Colleges and community colleges by providing mutually beneficial programmes that will up-skill those colleagues by giving them an opportunity to work with experienced UFS staff members. She says, “Reaching out to colleagues in TVET and Community colleges will offer them the opportunity to advance their lecturing and learning programmes, which will only lead to benefiting their learners and South Africa as a whole.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept